RESEARCH ARTICLE

Syndecan-4 Is an Independent Predictor of All-Cause as Well as Cardiovascular Mortality in Hemodialysis Patients

Andrzej J. Jaroszyński1,2,* , Anna Jaroszyńska3, Stanisław Przywara4, Tomasz Zaborowski2, Andrzej Książek5, Wojciech Dąbrowski6

1 Institute of Medical Sciences, Jan Kochanowski University in Kielce, Kielce, Poland, 2 Department of Family Medicine, Medical University of Lublin, Lublin, Poland, 3 Department of Cardiology, Medical University of Lublin, Lublin, Poland, 4 Department of Vascular Surgery, Medical University of Lublin, Lublin, Poland, 5 Department of Nephrology, Medical University of Lublin, Lublin, Poland, 6 Department of Anesthesiology and Intensive Care, Medical University of Lublin, Lublin, Poland

* jaroszynskiaj@interia.pl

Abstract

Background

Left ventricular hypertrophy is associated with increased mortality in hemodialysis (HD) patients. Syndecan-4 plays a role in many processes that are involved in the heart fibrosis and hypertrophy. We designed this study to prospectively determine whether syndecan-4 was predictive of mortality in a group of HD patients.

Methods

In total, 191 HD patients were included. Clinical, biochemical and echocardiographic parameters were recorded. HD patients were followed-up for 23.18 ± 4.02 months.

Results

Syndecan-4 levels correlated strongly with geometrical echocardiographic parameters and ejection fraction. Relations with pressure-related parameters were weak and only marginally significant. Using the receiver operating characteristics the optimal cut-off points in predicting all-cause as well as cardiovascular (CV) mortality were evaluated and patients were divided into low and high syndecan-4 groups. A Kaplan–Meier analysis showed that the cumulative incidences of all-cause as well as CV mortality were higher in high serum syndecan-4 group compared with those with low serum syndecan-4 (p<0.001 in both cases). A multivariate Cox proportional hazards regression analysis revealed syndecan-4 concentration to be an independent and significant predictor of all-cause (hazard ratio, 2.99; confidence interval, 2.34 to 3.113; p<0.001) as well as CV mortality (hazard ratio, 2.81; confidence interval, 2.28 to 3.02; p<0.001).
Conclusions

Serum syndecan-4 concentration reflects predominantly geometrical echocardiographic parameters. In HD patients serum syndecan-4 concentration is independently associated with all-cause as well as CV mortality.

Introduction

Cardiovascular (CV) disease is the leading cause of mortality in hemodialysis (HD) patients. The CV mortality rate of HD patients is much higher than that of the general population, even after adjustment for age, race, gender, and comorbidities [1–3]. Left ventricular hypertrophy (LVH) and cardiac fibrosis have been described as a frequent component of end-stage renal disease, and is observed in ~70% of dialysis patients. In HD patients LVH is mainly attributed to hypertension, anemia, volume overload, arteriovenous fistulas, hyperparathyroidism, arterial stiffening, and oxidative stress [4–6]. It is well established that LVH is strongly associated with increased mortality in HD patients [5–7].

Syndecans are major cell-surface heparan sulfate proteoglycans that are detected at the surface of most human cells. It consists of an ectodomain carrying heparin sulfate- or chondroitin sulfate-rich glucosaminoglycan chains, a transmembrane domain, and a short cytoplasmic tail [8–12]. Syndecan-4 connects extracellular matrix proteins to the cardiomyocyte cytoskeleton and mediates signals transduction pathways activated by growth factors and cell surface receptors. It can also cooperate with other molecules, including extracellular matrix components, enzymes, and clotting factors. Syndecan-4 plays a role in many processes including inflammation, wound healing tissue regeneration, and angiogenesis [12–17]. It has been demonstrated that syndecan-4 may play a role in collagen cross-linking, left ventricle stiffness, and cardiac fibrosis [9, 15, 16, 18], and is involved in cardiac injury and repair, including granulation tissue formation, and neovascularization after myocardial infarction [10, 11, 14, 19, 20]. Moreover, some recent clinical studies have demonstrated that syndecan-4 may be a useful biomarker for patients with cardiomyopathy [17, 21].

Given that syndecan-4 is the only syndecan with ubiquitous distribution (including heart and endothelial cells) [22–24], is essential for development of cardiac hypertrophy [15, 25], is required for endothelial alignment in flow, and is a potent antiatherosclerotic molecule [23], we hypothesized that it might be a potential biomarker useful in CV risk stratification in HD patients.

We designed this study to prospectively determine whether syndecan-4 was predictive of all-cause and CV mortality in a group of HD patients.

Subjects and Methods

Study population

The study included adult chronic HD patients treated at dialysis centers in Lublin (Poland). The exclusion criteria were: HD treatment less than 1 month, and advanced malignant diseases limiting the chance of a 3 months survival. All patients gave a written consent, and the studies were approved by members of the Ethical Committee of Medical University of Lublin.

Biochemical measurements

The following biochemical parameters were measured by automated analyzers at the beginning of the evaluation: sodium, potassium, calcium, phosphorus, Ca×P product, creatinine, urea,
hemoglobin, intact parathormone (PTH), C-reactive protein (CRP), total protein, albumin, total cholesterol, HDL cholesterol, triglycerides (TG), LDL cholesterol, and troponin T. Syndecan-4 as well as NT-proBNP were measured by the ELISA method (Biomedica, Poland). Serum syndecan-4 was also evaluated in 54 controls; the group’s gender distribution and age range were similar to the group of patients. Blood was obtained after at least 8 h fasting.

**Echocardiographic examination**

An experienced cardiologist who was blinded to the clinical data of the study subjects performed the echocardiographic studies according to the recommendations of the American Society of Echocardiography [26–28]. Left ventricle ejection fraction was calculated using a Simpson’s method. The LVM was calculated according to the formula of Devereux and Reichek [29] and this was indexed for body surface to obtain the LVMI. LVH was defined by an LVMI over 130 g/m$^2$ in males or over 110 g/m$^2$ in females. Ejection fraction < 50% was considered systolic dysfunction. All echocardiographic measurements were performed in the morning after dialysis [30].

**Follow-up data**

All patients were followed for at least 36 months from the baseline assessment or until death or renal transplant. All-cause mortality as well as CV mortality were used as endpoints. CV death was defined according to Standardized Definitions for End Point Events in Cardiovascular Trials [31]. All events were independently determined by two physicians. In the case of divergent opinions, the event was verified by an expert in cardiology.

**Statistical analysis**

Statistical analysis was carried out as described in detail previously [32]. Results were tested for normality by using Kolmogorov–Smirnov test. When normally distributed, continuous variables were expressed as mean ± SD, and as median and range when non-normally distributed. Categorical data were expressed as frequencies and percentages. Linear regression analysis was assessed using the Pearson correlation coefficient. When the distribution pattern did not match with normal distribution, data were converted by logarithmic transformation and then statistic tests were performed. The receiver operating characteristics curves (ROC) was to determine optimal cut-off points in predicting all-cause as well as CV mortality. The optimal cut-off value for syndecan-4 was defined as the value on the ROC curve that was associated with the minimum Euclidean distance from the curve to the upper left corner of the graph, using the following formula: 
\[
(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2
\]
[33]. For the survival analysis, patients were divided into groups according to the cut-off syndecan-4 level determined by the ROC analysis. Survival was measured beginning from the day of baseline examination until death or censoring. If patients underwent renal transplantation they were censored on the day of their last dialysis. Cumulative survival curves were constructed by using the Kaplan–Meier method for all-cause mortality and CV mortality. Differences between patient groups were assessed by use of the log-rank test. Relationships between baseline parameters and endpoints were analyzed with Cox proportional hazard regression analysis. In the univariate analyses, parameters that showed differences between high and low syndecan-4 groups were entered. Explanatory variables with a p value < 0.15 in the univariate analysis were entered into a multivariate analysis. Probability values of p < 0.05 were accepted as significant.
Results

Of the total of 202 HD patients initially identified, 7 patients were excluded due to advanced malignant diseases limiting the chance of a 3 months survival (4 patients) or treatment less than 1 month (3 patients). The remaining 195 HD patients (105 females and 90 males), aged 38–86 years (mean 69.6 ± 7.93), who remained on HD from 1 to 147 months (mean 46.33 ± 25.63) entered the study. The causes of end-stage renal disease (ESRD) were diabetes (n = 85), chronic glomerulonephritis (n = 40), hypertensive nephropathy (n = 21), polycystic kidney disease (n = 7), obstructive nephropathy (n = 6), chronic pyelonephritis (n = 4), and unknown/unsure (n = 32). Baseline characteristics for enrolled patients are shown in Table 1. Out of 195 patients who qualified for the study, 79.5% were taking angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 85.6% beta-blockers, and 60.5% statin. A history of myocardial infarction (%) 25.6 21.0 34.3 0.001

| parameter                              | All patients n = 195 | Low syndecan-4 n = 126 | High syndecan-4 n = 69 | p   |
|----------------------------------------|----------------------|-------------------------|------------------------|-----|
| Age (years)                            | 69.5 ± 7.95          | 66.7 ± 7.08             | 74.6 ± 6.35            | <0.001|
| HD vintage (months)                    | 46.2 ± 25.74         | 45.7 ± 24.78            | 47.1 ± 23.64           | 0.672|
| MI (%)                                 | 25.6                 | 21.0                    | 34.3                   | <0.001|
| Diabetes mellitus (%)                  | 57.1                 | 54.8                    | 61.2                   | 0.012|
| Hypertension (%)                       | 85.3                 | 86.3                    | 83.6                   | 0.341|
| Smoking                                | 13.1                 | 13.7                    | 11.9                   | 0.493|
| Beta-blockers (%)                      | 86.4                 | 83.1                    | 92.5                   | 0.001|
| ACE/ARB (%)                            | 75.4                 | 77.4                    | 71.6                   | 0.285|
| Statins (%)                            | 59.2                 | 60.5                    | 56.7                   | 0.393|
| E/e'(n)                                | 14.82 ± 5.28         | 13.96 ± 5.13            | 16.39 ± 4.77           | 0.011|
| LVMI (g/m²)                            | 144.2 ± 42.74        | 131.2 ± 41.83           | 169.3 ± 31.68          | <0.001|
| EF (%)                                 | 56.83 ± 6.33         | 54.72 ± 6.01            | 60.72 ± 5.76           | 0.001|
| LAVI (ml/m²)                           | 36.75 ± 8.24         | 35.24 ± 7.24            | 38.34 ± 7.75           | 0.012|
| Hemoglobin (g/dL)                      | 11.07 ± 1.21         | 11.03 ± 0.98            | 11.21 ± 1.22           | 0.590|
| Total cholesterol (mg/dL)              | 187.4 ± 37.35        | 188.1 ± 37.11           | 186.0 ± 35.87          | 0.674|
| LDL cholesterol (mg/dL)                | 116.9 ± 31.03        | 116.1 ± 30.13           | 118.3 ± 28.02          | 0.632|
| HDL cholesterol (mg/dL)                | 43.12 ± 18.11        | 43.4 ± 17.86            | 42.67 ± 14.45          | 0.711|
| Triglycerides (mg/dL)                  | 172.1 ± 61.24        | 170.2 ± 59.54           | 175.7 ± 54.9           | 0.314|
| PTH, range (pg/mL)                     | 394 (0.0–1212)       | 375 (0.0–924)           | 466 (0.0–1212)         | 0.215|
| Albumin (g/dL)                         | 3.68 ± 0.37          | 3.69 ± 0.36             | 3.61 ± 0.32            | 0.775|
| CRP, range (mg/dL)                     | 7.98 (0.22–112.1)    | 5.34 (0.22–67.4)        | 9.72 (1.18–112.1)      | 0.132|
| Troponin T, range (μg/L)               | 0.051 (0.00–0.775)   | 0.034 (0.00–0.379)      | 0.098 (0.032–0.775)    | 0.021|
| NT-proBNP (fmol/ml)                    | 301.3 ± 135.4        | 276.7 ± 125.9           | 346.9 ± 101.8          | 0.096|
| Sodium (mmol/L)                        | 137.8 ± 2.63         | 137.7 ± 2.61            | 138.0 ± 2.69           | 0.874|
| Potassium (mmol/L)                     | 5.73 ± 0.72          | 5.69 ± 0.74             | 5.82 ± 0.63            | 0.642|
| Calcium (mmol/L)                       | 2.48 ± 0.25          | 2.49 ± 0.25             | 2.47 ± 0.25            | 0.612|
| Phosphate (mmol/L)                     | 2.24 ± 0.39          | 2.21 ± 0.23             | 2.30 ± 0.29            | 0.102|
| Ca x P product mg²/dl²                 | 48.51 ± 10.62        | 46.9 ± 9.69             | 51.33 ± 9.87           | 0.024|

CAD—coronary artery disease; MI—history of myocardial infarction; ACE/ARB—angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; LVEDd—left ventricular end-diastolic diameter; LVESd—left ventricle end-systolic diameter; PWDD—posterior wall diastolic diameter; PWSd—posterior wall systolic diameter; IVSDd—interventricular septum enddiastolic diameter; IVSSd—Interventricular septum end systolic diameter; E/e’—early transmitral flow velocity / early diastolic velocity of the mitral valve annulus; LVM—Left ventricular mass; LVMi—Left ventricular mass index; LVH—Left ventricular hypertrophy; EF—Ejection fraction; LAVI—Left atrial volume index; PTH—parathormon; CRP—C-reactive protein; NT-proBNP—N-terminal pro-hormone brain natriuretic peptide.

doi:10.1371/journal.pone.0163532.t001
Infarction (MI) was present in 25.1% of patients and 52.8% were diabetic. Hypertension was observed in 85.1% of patients. LVH was found in 66.1% of patients, systolic dysfunction was found in 24.1%. Serum syndecan-4 was higher in patients compared with controls (15.9 ± 9.78 and 5.04 ± 2.08 respectively, \( p < 0.001 \)).

The results of univariate linear regression analysis showed significant, however weak correlation between serum syndecan-4 and NT-proBNP concentrations. The relation between syndecan-4 and troponin T was not significant. Similarly, there was no dependence of syndecan-4 on gender or age. With regard to echocardiographic parameters syndecan-4 levels correlated with geometrical parameters (LVMI, LVEDd, IVSd, PWd), ejection fraction, as well as pressure-related parameters (E/e', LAVI). It should be noted, however, that relations with pressure-related parameters were weak and only marginally significant. Relationship between serum syndecan-4 and biochemical as well echocardiographic parameters are depicted in Table 2.

The ROC characteristics curves were created to determine optimal cutoff points in predicting all-cause as well as CV mortality. With regard to all-cause mortality the value for \( (1 – \text{sensitivity})^2 + (1 – \text{specificity})^2 \) was minimal when the serum syndecan-4 level was 22.6 ng/ml (sensitivity of 71.4% and specificity of 84.1%). In the case of CV mortality the optimal cut-off point was 21.9 ng/ml (sensitivity of 70.4% and specificity of 85.3%). In 68 patients (34.9%) serum syndecan-4 exceeded 22.6 ng/ml, and in 69 (35.5%) patients syndecan-4 was above 21.9 ng/ml. Given that optimal cut-off values for both all-cause and CV mortality were very similar, for further analysis the lower level was assumed. On the basis of optimal cut-off value patients were divided into low and high serum syndecan-4 groups.

High syndecan-4 patients were older \(( p < 0.001)\), more often had a history of MI \(( p < 0.001)\), had higher prevalence of diabetes mellitus \(( p = 0.012)\), and were more likely to be on beta blocker therapy \(( p = 0.001)\). With regard to echocardiographic parameters, high syndecan-4 patients had higher LVMI \(( p < 0.001)\), LAVI and E/e' values \(( p = 0.012 \text{ and } p = 0.011, \text{ respectively})\) and lower EF \(( p < 0.001)\) in comparison to patients with low syndecan-4 patients. With regard to biochemical parameters, high syndecan-4 patients had higher troponin T level \(( p = 0.021)\) as well as Ca x P product \(( p = 0.024)\).

Over the mean follow-up period of 25.08 ± 4.32 months (range 1–36 months), there were 76 all-cause deaths (39.0%), and the mortality rate was 13% per year. CV deaths accounted for

### Table 2. Associations between syndecan-4 and echocardiographic as well as biochemical parameters.

| parameter       | \( r \) | \( p \) |
|-----------------|--------|--------|
| Age             | 0.121  | 0.109  |
| HD vintage      | 0.073  | 0.312  |
| EF              | -0.531 | <0.001 |
| LVEDd           | 0.446  | <0.001 |
| IVSd            | 0.371  | <0.001 |
| PWd             | 0.332  | <0.001 |
| LVMI            | 0.421  | <0.001 |
| E/e'            | 0.208  | 0.011  |
| LAVI            | 0.199  | 0.014  |
| NT-proBNP       | 0.201  | 0.013  |
| Troponin T      | 0.075  | 0.324  |

LVEDd–left ventricular end-diastolic diameter; IVSd–interventricular septum enddiastolic diameter; PWd–posterior wall diastolic diameter; LVMI–left ventricle mass index; E/e'—early transmitral flow velocity / early diastolic velocity of the mitral valve annulus; LAVI–left atrial volume index

doi:10.1371/journal.pone.0163532.t002
52.6% of all death. Eleven patients were transplanted. The incidence of all-cause deaths was as follows: in high syndecan-4 group 58.1% and in low syndecan-4 group 27.8% (p < 0.001). The incidence of CV mortality was as follows: in high syndecan-4 group 40.1% and in low syndecan-4 group 17.9% (p < 0.001). All but one transplanted patients came from the high syndecan-4 group.

A Kaplan–Meier analysis showed that the cumulative incidence of all-cause mortality was significantly higher in high syndecan-4 patients compared to low syndecan-4 group (log-rank, p < 0.001; Fig 1). Similarly, a Kaplan–Meier analysis showed that the cumulative incidence of CV mortality was significantly higher in high syndecan-4 patients compared to low syndecan-4 group (log-rank, p < 0.001; Fig 2).

To control for possible confounders, multivariate analysis was performed using a model consisting of univariate predictors of cardiac mortality. The results of the univariate and multivariate Cox proportional hazard regression analyses are shown in Tables 3 and 4. A multivariate analysis selected age [hazard ratio (HR) 1.57, p < 0.001], syndecan-4 [HR 2.99, p < 0.001], and troponin T [HR 1.55; p = 0.025] as well as age [HR 1.70, p < 0.001], syndecan-4 [HR 2.81, p < 0.001], and LAVI [HR 2.28, p = 0.011] as independent predictors of all-cause and CV mortality, respectively.

Discussion

Our study generated three major findings: (i) serum syndecan-4 concentration is increased in HD patients compared with controls, (ii) serum syndecan-4 concentration correlated
predominantly with geometrical echocardiographic parameters, (iii) serum syndecan-4 level is an independent predictor of both all-cause and CV mortality in HD patients. Results of the present study have revealed that syndecan-4 level was higher in HD patients than in controls. It can result from the fact that LVH is prevalent in HD patients, and syndecan-4 is increased in proportion to the LVMI. The prevalence of LVH in our study (64.4%) was comparable to the prevalence of LVH reported by other authors [5, 7]. The other reason may be the accumulation of syndecan-4 as a result of kidney failure, however, according to our knowledge, the effect of renal function and influence of HD process on syndecan-4 metabolism remains unknown. It is difficult, however, to compare directly our results to the available data from other populations. This is largely due to the fact that syndecan-4 is not measured using reference standards.

In our study syndecan-4 correlated significantly both with geometrical and pressure-related echocardiographic parameters, however, relations between syndecan-4 and pressure-related parameters were weak and only marginally significant. Additionally, syndecan-4 correlated with EF. The results of the current study are in agreement with the results of Takahashi et al. [17], who also found relations between syndecan-4 and geometrical echocardiographic parameters as well as EF. In contrast to our results Takahashi et al. [17] have not revealed significant relations between syndecan-4 and pressure-related echocardiographic parameters as well as NT-proBNP. This may be due to differences between the studied groups of patients regarding the causes of cardiac hypertrophy. Overhydration is an important factor contributing to LVH in HD patients, and fluid overload is associated with pressure-related echocardiographic parameters, such as LAVI as well as E/e' [34, 35]. Syndecan-4 plays a role in a myriad of...
processes that are involved in the heart failure pathogenesis[12–17, 25, 36]. Results of previous studies have demonstrated that syndecan-4 is essential for development of cardiac hypertrophy [9, 15, 25], and syndecan-4 production is increased in the repair, but not undamaged region after myocardial infarction [10]. Weak relation between syndecan-4 and NT-proBNP may result from the fact that both biomarkers may represent somewhat different aspects of failing heart.

To our knowledge, this is the first study that has demonstrated the prognostic utility of syndecan-4 for predicting all-cause as well as CV mortality in HD patients. The Kaplan–Meier curves began to separate relatively early and then continued to stay separated until the end of follow-up for both all-cause as well as CV mortality. Moreover, multivariate Cox analysis revealed that syndecan-4 remained independent predictor after controlling for possibly confounders. The prognostic utility of syndecan-4 for predicting all-cause as well as cardiac death in HD patients is in concordance with some previous studies that have documented that

### Table 3. Uni- and multivariate predictors of all-cause mortality.

| Parameter              | Univariate HR(95% CI)     | p     | Multivariate HR(95% CI) | p     |
|------------------------|---------------------------|-------|-------------------------|-------|
| Age                    | 1.98 (1.46–2.41)          | <0.001| 1.57 (1.18–1.91)        | <0.001|
| Diabetes mellitus      | 1.45 (0.89–1.87)          | 0.009 | 1.12 (0.47–1.75)        | 0.347 |
| History of MI          | 1.42 (0.92–1.74)          | 0.005 | 1.39 (0.71–2.32)        | 0.178 |
| Beta-blockers          | 0.95 (0.51–2.32)          | 0.218 |                         |       |
| Calcium x phosphate product | 1.61 (0.84–3.22)      | 0.511 |                         |       |
| LVMi                   | 1.28 (0.66–2.25)          | 0.179 |                         |       |
| EF                     | 2.21 (1.65–3.23)          | 0.087 | 1.83 (0.82–3.42)        | 0.372 |
| E/e’                   | 2.49 (1.74–3.11)          | 0.011 | 1.78 (0.91–3.06)        | 0.245 |
| LAVI                   | 1.53 (1.12–2.14)          | 0.103 | 1.21 (0.75–2.57)        | 0.268 |
| Troponin T             | 2.13 (1.79–2.65)          | <0.001| 1.55 (0.94–1.93)        | 0.025 |
| Syndecan-4             | 2.94 (2.39–3.56)          | <0.001| 2.99 (2.34–3.11)        | <0.001|

HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; LVMi, left ventricular mass index; EF, ejection fraction; E/e’—early transmitral flow velocity / early diastolic velocity of the mitral valve annulus; LAVI—left atrial volume index. In the multivariate analyses, parameters with a p ≤ 0.15 were entered.

doi:10.1371/journal.pone.0163532.t003

### Table 4. Uni- and multivariate predictors of cardiovascular mortality.

| Parameter              | Univariate HR(95% CI)     | p     | Multivariate HR(95% CI) | p     |
|------------------------|---------------------------|-------|-------------------------|-------|
| Age                    | 1.12 (0.99–1.43)          | <0.001| 1.72 (0.91–1.62)        | <0.001|
| Diabetes mellitus      | 0.92 (0.41–1.97)          | 0.213 |                         |       |
| History of MI          | 1.42 (0.92–1.74)          | 0.005 | 1.39 (0.71–2.32)        | 0.178 |
| Beta-blockers          | 1.04 (0.31–2.65)          | 0.348 |                         |       |
| Calcium x phosphate product | 1.51 (0.44–3.32)      | 0.547 |                         |       |
| LVMi                   | 2.98 (2.34–3.37)          | 0.005 | 2.25 (1.42–3.49)        | 0.138 |
| EF                     | 3.41 (1.85–5.13)          | 0.217 |                         |       |
| E/e’                   | 3.34 (2.16–4.21)          | 0.107 | 2.72 (1.44–3.75)        | 0.134 |
| LAVI                   | 2.93 (2.19–3.53)          | 0.002 | 2.28 (1.43–2.88)        | 0.011 |
| Troponin T             | 1.78 (1.09–2.54)          | 0.023 | 1.17 (0.59–2.31)        | 0.112 |
| Syndecan-4             | 3.43 (2.72–4.06)          | 0.001 | 2.81 (2.28–3.02)        | <0.001|

HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; LVMi, left ventricular mass index; EF, ejection fraction. In the multivariate analyses, parameters with a p ≤ 0.01 were entered.

doi:10.1371/journal.pone.0163532.t004
syndecan-4 is a useful biomarker for predicting cardiac death for patients with chronic heart failure [17] as well as for predicting adverse left ventricle remodeling in patients with dilated cardiomyopathy [21]. The pathophysiological mechanism of the association between syndecan-4 and HD patients mortality remains unknown. Syndecan-4 has been reported to promote hypertrophic response after myocardial infarction [15], and its level is elevated after myocardial infarction with a peak concentration corresponding to the repair phase [10]. Moreover, syndecan-4 plays a role in wound healing and angiogenesis [13]. Myocardial ischemia is the major reason of LVH in HD patients [5–7]. Coronary artery disease affects most of HD patients [32], and moreover HD process per se can induce transient myocardial ischemia (myocardial stunning), that may lead to myocardial dysfunction [37, 38]. Given that in our study syndecan-4 correlated with geometrical echocardiographic parameters and LVH, we can hypothesized that elevated syndecan-4 may reflects the severity of defense mechanisms against ischemia induced myocardial damage as well as may atherosclerosis. Further studies are required to answer the question of whether syndecan-4 is merely a marker of poor prognosis that reflects the high prevalence of LVH, contributing to all-cause as well as CV mortality, or if it potentially identifies more distinct pathophysiological mechanisms that underlie increased mortality.

The present study has some important limitations. First, the numbers of patients in the study was relatively small. Nevertheless, the population was large enough to demonstrate a predictive value for syndecan-4. Second, it is possible that serial rather than single measurements of syndecan-4 may have changed the results, making syndecan-4 either more or less useful in predicting clinical events in HD patients. Third, the effect of renal function as well an HD process on syndecan-4 concentration remains unknown.

Conclusions

Serum syndecan-4 concentration reflect predominantly geometrical echocardiographic parameters. In HD patients serum syndecan-4 concentration is independently associated with all-cause as well as CV mortality.

Author Contributions

Conceptualization: AJJ WD AJ.
Formal analysis: TZ AK SP.
Funding acquisition: AJJ WD AK.
Investigation: AJJ AK AJ WD.
Methodology: AJJ TZ SP.
Project administration: AJJ.
Resources: AJJ AK.
Supervision: AJJ.
Validation: AJ.
Visualization: AJJ SP AJ.
Writing – original draft: AJJ AJ.
Writing – review & editing: AJJ AJ.
References

1. US Renal Data System: USRDS 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.

2. Cheung A, Samak M, Yan G, Berkoben M, Heyka R, Kaufman A et al. HEMO Study Group. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65: 2380–2390. doi: 10.1111/j.1523-1755.2004.00657.x PMID: 15149351

3. Herzog C, Ma J, Collins A. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799–805. doi: 10.1056/NEJM199809173391203 PMID: 9738087

4. Pun P. The interplay between chronic kidney disease, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis 2014; 21: 480–488. doi: 10.1053/j.ackd.2014.06.007 PMID: 25443573

5. Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med 2015; 5: 254–266. doi: 10.1159/000435838 PMID: 26648942

6. Paoletti E, De Nicola L, Gabbai F, Chiodini P, Ravera M, Pieracci L et al. Association of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol. 2016; 11: 271–279. doi: 10.2215/CJN.04860715 PMID: 26668021

7. Glassock R, Pecolts-Filho R, Barberato S. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Nephrol. 2009; Suppl 1: S79–91. doi: 10.2215/CJN.04860715 PMID: 19996010

8. Wu H, Zhou Q, Xie J, Li G, Chen Q, Kang L et al. Syndecan-4 shedding is involved in the oxidative stress and inflammatory responses in left atrial tissue with valvular atrial fibrillation. Int J Clin Exp Pathol. 2015; 8: 6387–6396. PMID: 26261514

9. Herum K, Lunde I, Skrbic B, Florholmen G, Behmen D, Sjaastad I et al. Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. J Mol Cell Cardiol. 2013; 54: 73–81. doi: 10.1016/j.yjmcc.2012.11.007 PMID: 23178899

10. Kojima T, Takagi A, Maeda M, Segawa T, Shimizu A, Yamamoto K et al. Plasma levels of syndecan-4 (Ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost. 2001; 85: 793–798. PMID: 11372670

11. Matsui Y, Ikesue M, Danzaki K, Morimoto J, Sato M, Tanaka S et al. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res. 2011; 108: 1328–1339. doi: 10.1161/CIRCRESAHA.110.235689 PMID: 21493899

12. Strand M, Herum K, Rana Z, Skrbic B, Askevold E, Dahl C et al. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J. 2013; 280: 2228–2247. doi: 10.1111/febs.12161 PMID: 23374111

13. Echtermeyer F, Harendza T, Hubrich S, Lorenz A, Herzog C, Mueller M et al. Syndecan-4 signalling inhibits apoptosis and controls NFAT activity during myocardial damage and remodelling. Cardiovasc Res. 2011; 92: 123–132. doi: 10.1093/cvr/cvr149 PMID: 21632883

14. Xie J, Wang J, Li R, Dai Q, Yong Y, Zong B et al. Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. J Mol Cell Cardiol. 2012; 53: 250–258. doi: 10.1016/j.yjmcc.2012.04.014 PMID: 22561100

15. Finsen A, Lunde I, Sjaastad I, Østli E, Lyngra M, Jarstadmarken H et al. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway. PLoS One. 2011; 6 (12): e28302. doi: 10.1371/journal.pone.0028302 PMID: 22164265

16. Samarel A. Syndecan-4: A component of the mechanosensory apparatus of cardiac fibroblasts. J Mol Cell Cardiol. 2013; 56: 19–21. doi: 10.1016/j.yjmcc.2012.12.008 PMID: 23266594

17. Takahashi R, Negishi K, Watanebe A, Arai M, Naganuma F, Ohyama Y et al. Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J Mol Cell Cardiol. 2011; 50: 325–332. doi: 10.1016/j.yjmcc.2011.01.012 PMID: 21397460

18. Strunz C, Matsuda M, Salemi V, Nogueira A, Mansur A, Cestari I et al. Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats. Cardiovasc Diabetol. 2011; 10: 35. doi: 10.1186/1745-2840-10-35 PMID: 21518435

19. Kunnas T, Nikkari S. Contribution of syndecan-4 genetic variants to hypertension, the TAMRISK study. BMC Res Notes. 2014; 7: 815. doi: 10.1186/1756-0500-7-815 PMID: 25410619

20. Vuong T, Reine T, Sudworth A, Jenssen T, Kolset S. Syndecan-4 is a Major Syndecan in Primary Human Endothelial Cells In Vitro, Modulated by Inflammatory Stimuli and Involved in Wound Healing. J Histochem Cytochem. 2015; 63: 280–292. doi: 10.1369/002215541568995 PMID: 25575567
21. Bielecka-Dabrowa A, von Haehling S, Aronow W, Ahmed M, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol. 2013; 168: 2404–2410. doi: 10.1016/j.ijcard.2013.01.157 PMID: 23416015

22. Teng Y, Aquino R, Park P. Molecular functions of syndecan-1 in disease. Matrix Biol 2012; 31: 3–16. doi: 10.1016/j.matbio.2011.10.001 PMID: 22033227

23. Baeyens N, Mulligan-Kehoe M, Corti F, Simon D, Ross T, Rhodes J et al. Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling. Proc Natl Acad Sci 2014; 111: 17308–17313. doi: 10.1073/pnas.1413725111 PMID: 25404299

24. Sueta D, Hokimoto S. Could Circulatory Syndecan-1 Be a Predictable Biomarker for Acute Kidney Injury in Patients With Acute Decompensated Heart Failure? Circ J 2015; 79: 1444–1445. doi: 10.1253/circj.CJ-15-0552 PMID: 26027446

25. Xie J, He G, Chen Q, Sun J, Dai Q, Lu J et al. Syndecan 4 signaling is required for exercise-induced cardiac hypertrophy. Mol Med. 2016. doi: 10.2119/molmed.2015.00026

26. Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39. doi: 10.1073/pnas.1413725111 PMID: 25559473

27. Naghesh S, Appelton C, Gilibert T, Marino P, Oh J, Smiseth O et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. Eur J Echocardiogr. 2009; 10: 165–193. doi: 10.1093/ejchoe/jep007 PMID: 19270053

28. Hickson L, Negrotto S, Onuigbo M, Scott C, Rule A, Norby S et al. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis. J Am Coll Cardiol. 2016; 67: 1173–1182. doi: 10.1016/j.jacc.2015.12.052 PMID: 26965538

29. Devereux R, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation.1977; 55: 613–618. PMID: 138494

30. Stewart G, Gansevoort R, Mark P, Rooney E, McDonagh T, Dargie H et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005; 67: 217–26. doi: 10.1111/j.1523-1755.2005.00072.x PMID: 15610245

31. Hicks K, Hung H, Mahaffrey K, Mehran R, Nissen S, Stockbridge N et al. Standardized definitions for end point events in cardiovascular trials. 2014. http://www.cdisc.org/stuff/contentmgr/files/0/2356ae38ac190ab8ca4ae0b222392b37/misc/cdicnوفember_16__2010.pdf.

32. Jaroszyński A, Jaroszyńska, Siebert J, Dąbrowski W, Niedziałek J, Bednarek-Skubleska A, Zapolski T et al. The prognostic value of positive T-wave in lead aVR in hemodialysis patients. Clin Exp Nephrol 2015; 19: 1157–1164. doi: 10.1007/s10157-015-1100-8 PMID: 25724127

33. Sereide Kjellin. Receiver-operating characteristic (ROC) curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol doi: 10.1136/jcp.2008.061010

34. Yilmaz A, Yilmaz B, Küçükseymen S, Özpełt E, Pekel N. Association of overhydration and cardiac dysfunction in patients have chronic kidney disease but not yet dialysis. Nephrol Ther 2016; 12: 94–97. doi: 10.1016/j.nephro.2015.08.003 PMID: 26612488

35. Juan-García I, Puchades M, Sanjuan R, Torregrosa I, Solis M, Gonzales M et al. Echocardiographic impact of hydration status in dialysis patients. Nefrologia. 2012; 32: 94–102. doi: 10.3265/Nefrologia.pre2011.Nov.10867 PMID: 2240880

36. Elfenbein A, Simons M. Syndecan-4 signaling at a glance. J Cell Sci 2013; 126: 3799–3804. doi: 10.1242/jcs.124636 PMID: 23970415

37. McIntyre C. Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purif 2010; 29: 105–110. doi: 10.1159/000245634 PMID: 20093813

38. Assa S, Humm el Y, Voors A, Kuipers J, Westerhuis R, de Jong P et al. Hemodialysis-induced regional left ventricular systolic dysfunction; prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012; 7: 1615–1623. doi: 10.2215/CJN.00850112 PMID: 22822014